30 closest matches · ranked by relevance
Chronic Troublesome Sialorrhea · Parkinson's Disease · Post-stroke
Primary: MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 4 — -0.04; -0.06; -0.13 gram per minute (g/min) — p== 0.004
Sialorrhea
Primary: Objectively Measured Salivary Weight — -0.07; -0.68 gm
Sialorrhea
Primary: Occurrence, Seriousness, Severity, and Causality Assessment of Treatment Emergent Adverse Events (TEAE) — 7; 14; 3; 2 participants
Sialorrhea
Primary: Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A) — -0.37; -0.36; -0.07 g/minute — p=<0.0001
Chronic Troublesome Sialorrhea · Cerebral Palsy · Stroke
Primary: Change From Baseline in Unstimulated Salivary Flow Rate (uSFR) at Week 4 — -0.07; -0.14 gram per minute (g/min) — p== 0.0012
Sialorrhea Secondary to Parkinson's Disease
Primary: Sialorrhea Visual Analogue Scale (VAS) — -0.55; -1.08; -1.53; -0.81 cm on VAS — p=0.6
Drooling
Primary: Change in Drooling Frequency & Severity Scale (DFSS)at Wk 4 Post-injection — -2.1; -3.3; -3.5; -1.3 points on a scale
Cerebral Palsy · Neurological Conditions · Mental Retardation
Primary: Proportion of Responders According to the Modified Teacher's Drooling Scale (mTDS) — 68; 62; 7 Participants
Sialorrhoea
Primary: Saliva Secreted Rate — -6.508; -34.512; 83.695; 7.414 percentage of change from baseline
Xerostomia · Depression · Hypertension
Primary: Dry Mouth Questionnaire (DMQ) — 3.4; 1.4 units on a scale
Xerostomia
Primary: Change in Dry Mouth Symptom by Visual Analog Scale at 14 Days From Baseline — 10.1; 11.6; 13.0 mm
Sialorrhea
Primary: Difference in Salivary Flow Rate (ml/Min) Between Study Groups — .072; .003; NA ml/min
Xerostomia
Primary: Mean Response to the Question 1 'Relieving the Discomfort of Dry Mouth' in Product Performance and Attributes Questionnaire 3 (PPAQ3) at 120 Minutes(Mins) Post Treatment…
Dry Mouth
Primary: Change From Baseline in Saliva Production in ml. — 1.41; 3.93; 5.31; 10.34 ml — p=0.05
Edentulous Jaw · Edentulous Mouth
Primary: Change From Baseline in Patient Comfort for as Assessed by Numerical Scale. — 0.99; 1.16 units on a scale
Dry Mouth · Xerostomia
Primary: Change in VAS for Mouth Dryness — -0.8; -0.7; -1.5; -0.4 score on a scale — p=<0.01
Xerostomia
Primary: Change in Percentage of Time With CPAP (Continuous Positive Airway Pressure) Usage — -5.09; 11.67 percentage of time
Dry Mouth
Primary: Response to "Relieving the Discomfort of Dry Mouth" From the Modified PPAQ I 4- and 6-hours Post-use on Day 1 of Treatment — 2.51; 3.26; 3.43 score on a scale
Dry Eye Syndromes · Sjogren's Syndrome
Primary: Schirmer Testing — 10.2; 0.8; 13.5 mm.
Xerostomia
Primary: Subjective Perception of Mouth Dryness — 6.92; 6.46; 4.21; 3.46 units on a scale — p=.45
KERATOCONJUNCTIVITIS SICCA · XEROSTOMIA · SICCA SYNDROME
Primary: The Xerostomia Inventory — 40.2; 39.3 units on a scale — p=0.05
Xerostomia · Sjogren Syndrome · Dry Mouth
Primary: Change in Salivary Flow From Baseline — 0.17; 0.10; 0.66; 0.04 ml/min
Xerostomia · Sjogren's Syndrome
Primary: Overall Improvement Rate in Dry Mouth Symptoms — 26.0; 20.0; 44.0; 27.1 percentage of participants
Hyposalivation
Primary: Fluoride Concentration in Dental Biofilm Fluid at Baseline — 0.24; 0.22 parts per million (ppm) of fluoride — p=0.8412
Xerostomia · Head and Neck Cancer · Xerostomia Following Radiotherapy
Primary: Oral Dryness — 45.5; 46.6; 52.76; 54.1 units on a scale — p=<0.501
Head and Neck Cancer · Xerostomia
Primary: Phase II: Treatment Compliance (Number of Compliant Patients) — 12; 44 Participants
Cough · Superior Laryngeal Nerve Block · Neurogenic Cough
Primary: Change in Cough Severity — 13.15; 9.54 LCQ scores (baseline to 3 months)
Xerostomia
Primary: 10 cm Mouth Dryness Visual Analog Score — 4.51; 4.6 cm
Amyotrophic Lateral Sclerosis · Parkinson Disease · Dysphagia
Primary: Number of Participants With Residue of Concern (Observational) — 6; 6; 3; 6 Participants
Parkinson's Disease · Deglutition Disorders · Voice Disorders
Primary: Oropharyngeal Swallowing Score — 22.15; 21.93 Scores on a scale